Download presentation

Presentation is loading. Please wait.

Published byShane Twiddy Modified over 2 years ago

1
The Search for Synergism A Data Analytic Approach L. Wouters, J. Van Dun, L. Bijnens May 2003 Three Country Corner Royal Statistical Society

2
2Overview Combined action of drugs Screening for synergism Experimental Design Fitting concentration response curves, estimation of IC 50 Graphical analysis of combined action –isobolograms –fraction plots –combination index

3
3 Drug Combinations Additive Sub-additive: antagonism fight against one another Super-additive: synergism work together

4
4 Drug Combinations: Antagonism - Synergism Major therapeutic areas: –Oncology –Infectious disease Ideal combination: –Synergistic for therapeutic activity –Antagonistic for toxicity

5
5 Non-additivity and Statistical Interaction Drug A f(x), drug B g(x) Combination: a + b, h(a,b) f(a) = 50 %, g(b) = 60 % additivity h(a,b) = 110 % ? Drug can be antagonistic with itself f(a) = 0%, g(b)=0% additivity h(a,b) = 0% ? Drug can be synergistic with itself

6
6 Problems with Synergism - Antagonism Synergism is controversial issue Literature large but confusing Different definitions Different methods and experimental designs Pharmacological - biostatistical approaches Greco (1995) Pharmacol Rev 47: 331-385

7
7 Sarriselkä agreement (1992)

8
8 Loewe Additivity IC x,A, IC x,B concentrations required for each drug A, B individually to obtain a certain effect x (x % inhibition) Let C x,A, C x,B doses of drug A and drug B in the combination that jointly yield same effect x Drug A has lower potency IC x,A > IC x,B Relative potency of A: IC x,A / IC x,B

9
9 Loewe Additivity (cont.) Assume constant relative potency and additivity Combination can be expressed as equivalent concentrations of either drug :

10
10 Methods Based on Loewe Additivity Isobologram Interaction index of Berenbaum (1977) Bivariate spline fitting method of Sühnel (1990) Hypothesis testing approach of Laska (1994) Response surface methodology of Greco (1990), Machado (1994)

11
11Isobologram Synergy Antagonism

12
12 Bliss Independence i 1, i 2, i 12 inhibition as a fraction [0; 1] by drug 1, drug 2, and their combination from a probabilistic point of view, when fraction i 1 is inhibited by drug 1, only (1 - i 1 ) is available to respond to drug 2. Assuming independence: can be reformulated in terms of u. = 1 - i., the fraction remaining unaffected

13
13 Bliss Independence Counter-argument A drug can be synergistic with itself 75 % of control at 0.9 mg/kg Assume a dose of 0.9 mg/kg of the drug is combined with 0.9 mg/kg of the same drug Total dose = 1.8 mg/kg Under Bliss independence: 0.75 x 0.75 = 0.56 = 56 % for combination 1.8 mg/kg yields 15.7 % of control

14
14 Screening for Synergism in Oncology Screening experiment –as simple as possible with limited resources –carried out on a routine basis –analysis must be automated Screening experiments on tumor cells grown in 96-well microtiter plates

15
15 Screening Experiment Requirements –Unbiased estimates of responses –Avoidance of confounding of random error and drug effects –Elimination of plate effects and plate location effects in 96-well plates

16
16 Plate Location Effects in 96-well Plates Microtiter plates contain a substantial amount of unexplainable systematic error along their rows & columns (Faessel, et al. 1999) Importance of standardization experiment (low, middle, and high response)

17
17 Standardization Experiment (n = 3) Standardization experiment at high level of response, n=3 Within assay presence of systematic differences of important magnitude (up to 50 %) in untreated microtiter plates after edge removal Not repeatable between different runs of assay

18
18 How to Eliminate Bias & Confounding ? Randomization assures: –Equal probability to attain a specific response for each well –Independence of results –Absence of confounding –Proper estimation of random error

19
19 Experimental Design Ray Design Mixtures are composed based on preliminary estimates of IC 50 of constituents Assuming additivity: Construct concentration response curve for different mixture factors: DrugADrugA Drug B

20
20 Ray Design Composition of Mixtures Tested concentration C i of mixture is composed of: Proportion of constituents in mixture: DrugADrugA Drug B

21
21 Advantages of strategy Simplified analysis: –Consider mixture as new drug –Fit concentration response curve to different dilutions of mixture Easy to carry out in laboratory Limited number of samples

22
22 Layout of Screening Experiments in Oncology Ray design reference compound A, tested compound B f = 0, 0.125, 0.25, 0.5, 0.75, 1 Experiments carried out in 3 independent 96-well plates Dilutions (k): 10/1, 10/2, 10/3, 10/4, 1/1, 1/2, 1/4, 1/10 All dilutions tested within single plate Wells for background and maximum effect Allocation of different treatment is randomized within plate by robot

23
23 Experimental Data

24
24Percentages

25
25 Lessons from EDA Asymptotes of sigmoidal curve not reached always Some part of sigmoidal curve is still present Computing percentages makes sense (common system maximum) Proposed functional model:

26
26 Fit of 2 Parameter Logistic Ignoring Plate

27
27 Individual Fits of 2 Parameter Logistic per Plate

28
28 Studentized Residuals versus Fitted Values after Individual Model Fitting

29
29 Normal Quantile Plot of Pooled Residuals after Individual Model Fits

30
30 Individual Estimates per Plate-Factor

31
31 Lessons from EDA for Functional Model Fitting Sigmoidal shape as described by 2-parameter logistic model Importance of plate effect even after correcting for background, etc. by calculating percentages How to obtain reliable estimate of IC 50 and standard errors ?

32
32 Nonlinear Mixed Effects Nonlinear Mixed Effects Model (Pinheiro, Bates) allows to model individual response curves within plates and provides reliable estimate of standard error Result = estimates and standard errors of model parameters as fixed effects

33
33Isobologram Synergism Antagonism Decompose IC 50,M of mixture into IC 50 of constituents C 50,A and C 50,B : Plot of drug B versus drug A and line of additivity

34
34 Fraction Plot Based upon refined estimates of IC 50 of Drug A and B recalculate the correct fraction f : Plot of IC 50 of mixture versus recalculated fraction

35
35 Combination Index Chou and Talalay (1984) 95% Confidence intervals by parametric bootstrap (n = 10000) based upon estimates and standard errors from nlme fit

36
36Conclusions Present graphical approach appealing to scientists Still a lot to be done –T. O’Brien’s approach (TOB) –Incorporating design issues in TOB –Alternative distributions (e.g. gamma) –Optimal design

Similar presentations

OK

Ming T Tan, PhD University of Maryland Greenebaum Cancer Center 2006 D.O.E. Presentation 7/11/2006 Optimized Experimental.

Ming T Tan, PhD University of Maryland Greenebaum Cancer Center 2006 D.O.E. Presentation 7/11/2006 Optimized Experimental.

© 2017 SlidePlayer.com Inc.

All rights reserved.

Ads by Google